Streetbeat News

Stock Prices

BBWI

Bath & Body Works (NYSE:BBWI) reported Q2 earnings per share of 37 cents, beating expectations, but sales fell short at $1.526 billion. The company revised its FY24 sales and EPS forecasts downward, and shares fell 4.95% premarket. CEO Gina Boswell emphasized the company's strong cash flow and plans for share repurchases.

Portfolio Pulse from Nabaparna Bhattacharya

August 28, 2024 | 12:11 pm

AMBA

ANF

VRAX

Virax Biolabs, Ambarella, and Abercrombie & Fitch experienced significant stock movements. Virax Biolabs surged 35% due to a new distribution agreement for Mpox virus detection kits. Ambarella rose 23% after surpassing Q2 earnings expectations. Abercrombie & Fitch fell 10% amid uncertain market conditions.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:10 pm

ARM

ET

PAYX

RTX

Jim Cramer expressed his views on several stocks on CNBC's 'Mad Money Lightning Round.' He favors RTX Corporation as his top defense stock and is optimistic about Arm Holdings, which he believes is accelerating despite a price drop. Cramer also sees Energy Transfer's dividend as safe and recommends buying Paychex, Inc. for its yield.

Portfolio Pulse from Avi Kapoor

August 28, 2024 | 12:07 pm

COCH

Envoy Medical, a company focused on fully implanted hearing devices, has secured a $10 million lending facility, drawing $5 million initially. This funding, provided by major shareholder Glen Taylor, supports the company's growth and milestone achievements.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:07 pm

ASTS

AST SpaceMobile (NASDAQ:ASTS) will redeem all outstanding publicly traded warrants for $0.01 each on September 27, 2024, after meeting the stock price condition of at least $18.00 for 20 days within a 30-day period. Warrant holders can exercise their warrants for $11.50 each until the redemption date.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:06 pm

VXRT

Vaxart has announced promising preclinical data for its mucosal vaccine technology, which shows potential in treating HPV-related tumors. The vaccine stimulated an immune response, reduced tumor size, and increased survival in an animal model, indicating potential for non-invasive treatment of HPV-related cervical dysplasia.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:04 pm

FL

Foot Locker reported a Q2 adjusted EPS loss of 5 cents, beating expectations, and sales of $1.896 billion, also surpassing estimates. Despite positive sales growth and margin expansion, the stock fell 8.11% premarket due to store closures and a cautious outlook.

Portfolio Pulse from Anusuya Lahiri

August 28, 2024 | 12:03 pm

ASTS

AST SpaceMobile announced it will redeem all publicly traded warrants to purchase Class A common shares that remain outstanding as of 5:00 p.m. on September 27.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:03 pm

LEGN

Legend Biotech (NASDAQ:LEGN) has received mixed analyst ratings over the past three months, with a majority being bullish. The average 12-month price target has increased to $77.93. The company has shown significant revenue growth but faces challenges in ROE and ROA.

Portfolio Pulse from Benzinga Insights

August 28, 2024 | 12:01 pm

MMSI

Merit Medical Systems (NASDAQ:MMSI) has received mixed analyst ratings over the past three months, with a majority being bullish or somewhat bullish. Analysts have set a 12-month average price target of $100.56, indicating a positive outlook. The company shows strong financial health with impressive net margins and efficient asset utilization.

Portfolio Pulse from Benzinga Insights

August 28, 2024 | 12:00 pm